NV-5138 as a fast-acting antidepressant via direct activation of mTORC1 signaling
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Growing evidence implicates altered mTORC1 signaling cascades in the pathophysiology of depression, suggesting that direct modulation of mTORC1 signaling may offer novel therapeutic potential. In this issue of the JCI, Kato and colleagues reported that administration of NV-5138, a recently developed synthetic leucine analog, has a rapid and sustained antidepressant action in rat models via activation of mTORC1 signaling. The investigators also found that the antidepressant effect of NV-5138 is mediated by upregulation of brain-derived neurotrophic factor (BDNF) signaling and that NV-5138 treatment produces rapid synaptic responses in the medial prefrontal cortex. These findings highlight the direct activation of mTORC1 signaling as a potential pharmacological intervention for the treatment of depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, direct activation of the mTORC1 pathway via NV-5138 produces antidepressant effects in rats, suggesting that mTORC1 activation alone may be sufficient to alleviate depressive symptoms 231.”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [231]
In the citing paper
“Furthermore, direct activation of the mTORC1 pathway via NV-5138 produces antidepressant effects in rats, suggesting that mTORC1 activation alone may be sufficient to alleviate depressive symptoms 231.”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [231]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“Importantly, the N-methyl-daspartate (NMDA) glutamate receptor antagonist ketamine, a widely used anesthetic, has a rapid-acting antidepressant effect, even in treatment-resistant patients (4, 5).”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · cited 2×
“Importantly, the N-methyl-daspartate (NMDA) glutamate receptor antagonist ketamine, a widely used anesthetic, has a rapid-acting antidepressant effect, even in treatment-resistant patients (4, 5).”
BackgroundmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737 · cited 1×
“Limitations of currently available antidepressants Major depressive disorder (MDD) is a common psychiatric disorder which imposes substantial public health burden and has a high lifetime prevalence (1).”
BackgroundGenetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior
Chen, Z.-Y., Jing, D., Bath, K. G., Ieraci, A., Khan, T., Siao, C.-J., Herrera, D. G., Toth, M., Yang, C., McEwen, B. S., et al. (2006) · Science · doi:10.1126/science.1129663 · Cited by 1,340
Sestrin2 is a leucine sensor for the mTORC1 pathway
Wolfson, R. L., Chantranupong, L., Saxton, R. A., Shen, K., Scaria, S. M., Cantor, J. R., & Sabatini, D. M. (2016) · Science · doi:10.1126/science.aab2674 · Cited by 1,306
Li, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082
Cited by
Yan, Z., & Rein, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01092-3 · Cited by 300
Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262
“The role of mTOR in antidepressant action is also supported by evidence of antidepressant activity of a direct mTOR activator [126, 127].”
BackgroundKohtala, S. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00232-4 · Cited by 142
“These efforts have not been entirely in vain because several studies have demonstrated the antidepressant-like behavioral actions of BDNF [231] as well as the direct activation of TrkB [232] and mTOR [233] in rodents.”
ResultNovel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00816-x · Cited by 142
“Animal models subsequently found that NV-5138 had rapid antidepressant effects [120, 121].”
BackgroundNovel drug developmental strategies for treatment‐resistant depression
Borbély, É., Simon, M., Fuchs, E., Wiborg, O., Czéh, B., & Helyes, Z. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15753 · Cited by 106
“These findings suggest that direct activation of mTORC1 signalling might be effective for depression therapy (Hasegawa et al., 2019; Kato et al., 2019), but Phase I/II study (NCT03606395) results have not yet confirmed the beneficial effect in humans (Table 1).”
BackgroundInfluentialRantamäki, T., & Kohtala, S. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018697 · Cited by 45
“Although this idea has turned out to be promising in some rodent studies (Shirayama et al., 2002; Chen et al., 2012; Fukuda et al., 2016; Hasegawa et al., 2019), it essentially ignores how these molecular events are part of activity-dependent synaptic plasticity (Changeux and Danchin, 1976; Thoenen, 1995; Hensch, 2005…”
BackgroundSESTRINs: Emerging Dynamic Stress-Sensors in Metabolic and Environmental Health
Ro, S., Fay, J., Cyuzuzo, C. I., Jang, Y., Lee, N., Song, H., & Harris, E. N. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.603421 · Cited by 37
“Recently, Navitor Pharmaceuticals developed Sestrin2-specific inhibitor, a leucine analog NV-5138, and try to treat the major depressive disorder (MDD) by activating mTORC1 in the brain (Hasegawa et al., 2019; Kato et al., 2019; Sengupta et al., 2019).”
BackgroundRapid acting antidepressants in the mTOR pathway: Current evidence
Athira, K. V., Mohan, A. S., & Chakravarty, S. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.07.022 · Cited by 37
Johnston, J. N., Thacker, J. S., Desjardins, C., Kulyk, B. D., Romay-Tallón, R., Kalynchuk, L. E., & Caruncho, H. J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.559627 · Cited by 27
“This brings about the possibility that rescuing hippocampal reelin may parallel ketamine’s actions in its fast-acting antidepressant effects, similar to other potential fast-acting antidepressant molecules that have been studied (Pazini et al., 2016; Hasegawa et al., 2019; de Almeida et al., 2020).”
BackgroundXu, Y., Zhang, J., Yu, L., Zhang, W., Zhang, Y., Shi, Y., Zhang, S., Li, C., & Tian, J. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17975 · Cited by 23
“31 These findings highlight the central importance of homeostatic control of mood circuit connections and form the basis of a synaptogenic hypothesis of depression and treatment response.”
BackgroundZhao, J., Jia, Y., Zhao, W., Chen, H., Zhang, X., Ngo, F. Y., Luo, D., Song, Y., Lao, L., & Rong, J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/7716201 · Cited by 14
“Interestingly, mTORC1 often cross-talks with mTORC2 to regulate the production of different cytokines [72].”
BackgroundDynamic analysis of 4E-BP1 phosphorylation in neurons with Tsc2 or Depdc5 knockout
Iffland, P. H., Barnes, A. E., Baybis, M., & Crino, P. B. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113432 · Cited by 11
Cheng, Z., Fan, J., Zhao, F., Su, J.-Y., Sun, Q., Cui, R.-J., & Li, B.-J. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.367928 · Cited by 7
“In addition, NV-5138, GLYX-13, hydrogen sulfide, zinc, and other fast-acting antidepressants have also been found to depend on the mTORC1 signaling pathway (Pałucha-Poniewiera et al., 2014; Szewczyk et al., 2015; Hou et al., 2017; Liu et al., 2017; Hasegawa et al., 2019).”
BackgroundHuntington’s disease phenotypes are improved via mTORC1 modulation by small molecule therapy
St-Cyr, S., Child, D. D., Giaime, E., Smith, A. R., Pascua, C. J., Hahm, S., Saiah, E., & Davidson, B. L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273710 · Cited by 3
The role of immunometabolism in HIV-associated depression and cognitive impairment
Andalibi, M. S. S., & Ellis, R. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99744-7.00028-6 · Cited by 4
Bulky substrates of isoleucine 2-epimerase: α-Neopentylglycine and NV-5138
Sorbara, N. T., Black, A. K. A., & Bearne, S. L. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130160 · Cited by 1
Where is the Mechanistic Target of Rapamycin Signaling Pathway in Depression?
Lee, J. A. (2022) · Mood and Emotion · doi:10.35986/me.2022.20.2.23 · Cited by 1
Meier, S., Larsen, A. S. G., Wanke, F., Mercado, N., Mei, A., Takacs, L., Mracsko, E. Z., Collin, L., Kampmann, M., Roudnicky, F., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.16.585330 · Cited by 2
“Since both mTORC1 activation reduced lipid burden irrespective of APOE levels, and the fact that brain penetrant mTORC1 activators have been identified and are now in clinical development 39,40 , this could represent a therapeutic approach to reduce glial lipid burden.”
BackgroundTakahashi, M., & Shelton, R. C. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2674645
“…compounds— including NMDA receptor positive allosteric modulators api-mostinel and zelquistinel [40], the NR2B-selective antagonist onfasprodil [41], and NV-5138, which acts via mTORC1 activation [42]—similarly target glutamatergic pathways to theoretically produce rapid clinical improvements.”
King, A., Hardy, M. S., Rhee, T. G., & Wilkinson, S. T. (2026) · CNS Drugs · doi:10.1007/s40263-026-01330-8
“Navitor Pharmaceuticals and Supernus Pharmaceuticals are jointly developing NV-5138 (also known as SPN-820 or mefluleucine), a small molecule that binds and modulates sestrin2, thereby activating the mTORC1 signaling pathway and promoting synaptogenesis [56].”
Metadata
- Authors
- Hasegawa, Y., Zhu, X., & Kamiya, A.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Kamiya, Atsushi
- Venue
- Journal of Clinical Investigation
- Published
- 2019-05-20
- Volume
- 129
- Issue
- 6
- Pages
- 2207-2209
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6546442
- OpenAlex
- W2945582051
- Cited by
- 20
- References
- 22
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 5 · 2020: 5
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (P50MH094268)
- National Institute on Drug Abuse (R01DA041208)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- mTORC1 signaling, antidepressant effects, depression, brain-derived neurotrophic factor, synaptic plasticity, medial prefrontal cortex, rapid-acting antidepressants
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Animals, Antidepressive Agents, Depression, Signal Transduction, Brain-Derived Neurotrophic Factor, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.